INFERTILITY DRUGS AND DEVICES MARKET ANALYSIS
Global Infertility Drugs and Devices Market: Key Developments
In January 2020, Evotec SE, a drug discovery and development company headquartered in Hamburg, Germany, and Bayer AG, a multinational pharmaceutical and biotechnology company in Germany, announced the expansion of its partnership in women’s health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”).
In September 2022, NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for chronic liver and related metabolic diseases and Dong-A ST Co., Ltd., a pharmaceutical company, announced that they have entered into a conditional exclusive license agreement for fertile to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of infertility.
In June 2022, Mankind Pharma, a pharmaceutical company in India, developed and launched a generic version of Dydrogestrone tablets for the treatment of patients’ pregnancy-related complications in India. This drug was an equivalent version of Abbott Duphaston tablets. This launch was expected to drive infertility treatment market.
Infertility Drugs And Devices Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :